On day 28 after tumor implantation and adoptive transfer, histomorphometric analysis confirmed that 4T1 tumors combined with 4T1-primed CD3+ T cells led to pronounced bone loss in vivo (25), a phenotype that was substantially reversed upon cotransfer of 67NR-primed CD19+ B cells (Fig. 2E). This evidence concerns the gene CD19 and neoplasm.